Avalyn Pharma Inc. Common Stock (AVLN) — Cash Flow-to-Debt Ratio
Avalyn Pharma Inc. Common Stock (AVLN) has a Cash Flow-to-Debt Ratio of -0.21x as of December 2025, meaning its operating cash flow of $-81.48 Million could theoretically repay 0% of its total liabilities ($387.54 Million) in one year. Explore Avalyn Pharma Inc. Common Stock long-term investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Avalyn Pharma Inc. Common Stock Cash Flow-to-Debt Ratio (2024–2025)
Historical debt coverage capacity for Avalyn Pharma Inc. Common Stock across 2 annual periods. Also explore Avalyn Pharma Inc. Common Stock assets under control for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Avalyn Pharma Inc. Common Stock (2024–2025)
Year-by-year debt coverage analysis for Avalyn Pharma Inc. Common Stock. For market capitalisation and broader financial context, see Avalyn Pharma Inc. Common Stock (AVLN) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.21x | $-81.48 Million | $387.54 Million | ▼ -30.0% |
| 2024 | -0.16x | $-48.37 Million | $299.04 Million | — |